分享产品介绍 评论(0)
物种
Bovine分子别名
LR3 Insulin-like Growth Factor-I,MGF,IGFI,IGF1A,IGF,IBP1,Accession
P07455表达序列
Gly50-Ala119 (Glu52Arg)表达宿主
E.coli分子量
9 kDa (Reducing)
纯度
>95% by SDS-PAGE.内毒素含量
<1EU/μg活性
EC50 < 0.5ng/ml标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
20mM NaAC, 20mM HAC, pH4.5溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
Carlson S W. et al. (2018) Central Infusion of Insulin-Like Growth Factor-1 Increases Hippocampal Neurogenesis and Improves Neurobehavioral Function after Traumatic Brain Injury. J Neurotrauma. 35(13):1467-1480.
IGF-I is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-I is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-II, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-I (rhLR3-IGF-I) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3-IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3) and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
生物活性
Measured in a serum-free cell proliferation assay using MCF7 human breast cancer cells. The ED50 for this effect is less than 0.5 ng/ml.
电泳
2μg (R: reducing condition, N: non-reducing condition).
评论(0)